Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease
- 28 February 2006
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 151 (2), 471-477
- https://doi.org/10.1016/j.ahj.2005.03.036
Abstract
In patients with pulmonary disease, it is often challenging to distinguish exacerbated pulmonary disease from congestive heart failure (CHF). The impact of B-type natriuretic peptide (BNP) measurements on the management of patients with pulmonary disease and acute dyspnea remains to be defined. This study evaluated the subgroup of 226 patients with a history of pulmonary disease included in the BASEL Study. Patients were randomly assigned to a diagnostic strategy with (n = 119, BNP group) or without (n = 107, clinical group) the use of BNP levels provided by a rapid bedside assay. Time to discharge and total cost of treatment were recorded as the primary end points. Baseline characteristics were similar in patients assigned to the BNP and control groups. Comorbidity was extensive, including coronary artery disease and hypertension in half of patients. The primary discharge diagnosis was CHF and exacerbated obstructive pulmonary disease in 39% and 33%, respectively. The use of BNP levels significantly reduced the need for hospital admission (81% vs 91%, P = .034). Median time to discharge was 9.0 days in the BNP group as compared with 12.0 days (P = .001) in the clinical group. Median total cost of treatment was $4841 in the BNP group as compared with $5671 in the clinical group (P = .008). Inhospital mortality was 8% in both groups. CHF is a major cause of acute dyspnea in patients with a history of pulmonary disease. Used in conjunction with other clinical information, rapid measurement of BNP reduced time to discharge and total treatment cost of these patients.Keywords
This publication has 23 references indexed in Scilit:
- Uncovering Heart Failure in Patients with a History of Pulmonary Disease: Rationale for the Early Use of B-type Natriuretic Peptide in the Emergency DepartmentAcademic Emergency Medicine, 2003
- Heart Failure — An Epidemic of Uncertain ProportionsNew England Journal of Medicine, 2002
- B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart FailureCirculation, 2002
- Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart FailureNew England Journal of Medicine, 2002
- Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) studyJournal of the American College of Cardiology, 2001
- ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure)Circulation, 2001
- Guidelines for the diagnosis and treatment of chronic heart failureEuropean Heart Journal, 2001
- DyspneaAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Causes of congestive heart failurePostgraduate Medicine, 1997
- Effects of prehospital medications on mortality and length of stay in congestive heart failureAnnals of Emergency Medicine, 1992